CTOs on the Move

Orb Health

www.orbhealth.com

 
The Orb® Platform automatically syncs health data from your doctor and your apps and wearable devices so you can own it, gives you context so can understand it and helps you improve it so you can transform. For consumers and patients, the Orb® Platform is a cloud-based health management platform that syncs and stores your personal health data from multiple doctor’s offices as well as your apps and wearable devices. On your computer or mobile device, Orb provides you with instant clarity and understanding behind your data while also providing actionable insight and solutions to help improve your health. For providers, the ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.orbhealth.com
  • 610 East Roosevelt Street Suite 134
    Phoenix, AZ USA 85004
  • Phone: 602.606.8927

Executives

Name Title Contact Details
Tyler Downs
Chief Technology Officer Profile
Jerry Kizziar
Chief Technology Officer Profile
Jerry Kizziar
Chief Technology Officer Profile

Similar Companies

Alive Hospice Of Nashville

Alive Hospice has been offering loving care to people with life-threatening illnesses, support to their families and service to the community in a spirit of enriching lives since 1975. As the oldest community-based hospice in Middle Tennessee, we

Colorado Health Care Association

Colorado Health Care Association is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rochester Medical Corporation

Rochester Medical Corporation is a Stewartville, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STATPROBE

STATPROBE, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.